Senseonics Rolls Out Eversense Subcutaneous Continuous Glucose Monitor
US FDA approved the Eversense CGM System for continually measuring glucose levels in adults with diabetes for up to 90 days, and the company is working on clinical evidence to support a 365-day indication, as well as working with Roche and Beta Bionics to include its sensor technology in fully integrated artificial pancreas systems
You may also be interested in...
Senseonics Holdings Inc. has appointed former Medtronic exec Francine Kaufman chief medical officer, effective immediately.
Market Intel: Needle-Free Glucose Monitoring, Digital Solutions Are Game-Changers In Growing Diabetes-Monitoring Market
The global blood glucose monitoring devices market is expected to exceed $7bn by 2022, driven by the smaller, but fastest-growing continuous glucose monitoring (CGM) segment, which is expanding at double-digits. The much bigger blood glucose meter (BGM) segment, meanwhile, is facing increased competition from lower-cost manufacturers, innovative startups and tech giants like Apple that are attracting consumers with smart devices and packaged diabetes management solutions. This first of a two-part series looks more closely at the competitive landscape of the two major product segments – BGM and CGM – with insights from endocrinologists. The second part will focus on the pros and cons of using diabetes management apps and highlights the best diabetes apps.
The leader in continuous glucose monitoring, Dexcom has acquired TypeZero Technologies, a specialist in developing algorithms for artificial pancreas systems. Does Dexcom have its sights on expanding beyond glucose monitoring and into insulin delivery, and building an artificial pancreas of its own?